ACL Healius Bid Bordering on the Pathological
Even though the Covid testing boom is over, Australian Clinical Labs still wants to create the country’s largest pathology provider by taking over the number one tester, Healius.
Read More
Healius Limited
One of Australia’s leading healthcare companies, Healius (formerly trading as Primary Health Care) is synonymous with quality, affordable and accessible healthcare for all Australians. Through an expansive network of multi-disciplinary medical centres, pathology laboratories and diagnostic imaging centres, Healius provides world class facilities and support services to independent General Practitioners, Radiologists and other Healthcare Professionals, enabling them to deliver quality care to their patients in partnership with Healius’ Pathologists, Nurses and other employees. Healius’ medical hub model makes healthcare services easily accessible and cost efficient, while supporting the coordination and continuity of quality patient care.
Videos
Videos coming soon for Healius Limited.
News
HLS – Morgans rates the stock as Add
The target price falls to $4.30 from $5.15 and the Add rating is maintained.
Read More
HLS – Macquarie rates the stock as Outperform
The Outperform rating and target price of $5.20 are retained.
Read More
HLS – Macquarie rates the stock as Outperform
After allowing for earnings revisions and an updated Macquarie risk-free rate, the target falls to $5.20 from $5.40, while valuation appeal sees the Outperform rating kept.
Read More
Tuesday Trading Talk: UWL, HLS
Corporate action afoot for a couple of industrial companies, with telco Uniti the subject of a takeover at $4.50 per share and healthcare provider Healius announcing a $A100m buyback.
Read More
HLS – Macquarie rates the stock as Outperform
The Outperform rating is retained and the target price increases to $5.40 from $5.30.
Read More
HLS – Credit Suisse rates the stock as Outperform
Outperform retained. Target rises to $5.50 from $5.35.
Read More
HLS – Credit Suisse rates the stock as Outperform
Outperform retained. Target is raised to $5.35 from $5.00.
Read More
HLS – Macquarie rates the stock as Outperform
Outperform retained. Target rises to $4.85 from $4.70.
Read More
HLS – Credit Suisse rates the stock as Outperform
The Australian government has announced an additional $1.1bn in funding for Australia's health response to covid-19 and will extend pathology testing for a further nine months to December 31 2021. Credit Suisse's Outperform retained. Target is $4.25.
Read More
